Bruton tyrosine kinase mediates TLR9 -dependent human dendritic cell activation
Background Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; howev...
Gespeichert in:
Veröffentlicht in: | Journal of allergy and clinical immunology 2014-06, Vol.133 (6), p.1644-1650.e4 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1650.e4 |
---|---|
container_issue | 6 |
container_start_page | 1644 |
container_title | Journal of allergy and clinical immunology |
container_volume | 133 |
creator | Lougaris, Vassilios, MD Baronio, Manuela, PhD Vitali, Massimiliano, PhD Tampella, Giacomo, PhD Cattalini, Marco, MD Tassone, Laura, PhD Soresina, Annarosa, MD Badolato, Raffaele, MD, PhD Plebani, Alessandro, MD, PhD |
description | Background Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; however, the TLR9 pathway has never been studied in dendritic cells (DCs) of patients with XLA. Objective The aim of this study was to investigate the role of BTK in human DC activation upon TLR9 stimulation. Methods DCs of patients with XLA and healthy donors were stimulated via TLR4/9 and evaluated for cell activation and cytokine production. Results We showed that BTK plays an essential role in DC responses to unmethylated CpG oligodeoxynucleotide: although responses to lipopolysaccaride/TLR4 induce normal DC activation in terms of upregulation of specific markers (CD86, CD83, CD80, HLA-DR), the CpG/TLR9 pathway is completely impaired in patients with XLA. Furthermore, cytokine production upon TLR9 activation in patients with XLA is radically impaired in terms of IL-6, IL-12, TNF-α, and IL-10 production. Interestingly, BTK mediated STAT1/3 upregulation in a TLR9-dependent manner. The important role of BTK in human DC activation was confirmed after incubation of healthy DCs with ibrutinib, the specific BTK inhibitor, which resulted in impairment of TLR9 responses as seen in patients with XLA. Conclusion Analysis of these data suggests that BTK regulates human DC responses upon TLR9 engagement in terms of activation, cytokine production, and STAT1/3 upregulation. These findings may be of important significance for better understanding and managing different clinical conditions, such as agammaglobulinemia and lymphoid malignancies. |
doi_str_mv | 10.1016/j.jaci.2013.12.1085 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1534814450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674914000840</els_id><sourcerecordid>1531954232</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-7b0647eae3dc2f3d8775481c73f0602973e1dde5f9aaece168729d9cb31f33db3</originalsourceid><addsrcrecordid>eNqNkltrFDEUgIModm39BYLMi-DLrDnJzCR5UKhFrbBQsPU5ZJMzmOlsZk0yhf33ZthVwRf7lAvfufCdQ8groGug0L0b1oOxfs0o8DWw8ifbJ2QFVIm6k6x9SlaUKqg70agz8iKlgZY3l-o5OWNNB6yTsCI3H-Ocp1DlQ5ySD1jd-2ASVjt03mRM1d3mm6pqh3sMDkOufsw7E6pyddFnbyuL41gZm_2DyX4KF-RZb8aEL0_nOfn--dPd1XW9ufny9epyU9uWsVyLLe0agQa5s6znTgrRNhKs4D3tKFOCIziHba-MQYvQScGUU3bLoefcbfk5eXvMu4_TzxlT1jufll5MwGlOGlpe8jVNSx-DgmobxllB-RG1xUaK2Ot99DsTDxqoXqTrQS_S9SJdA9OL9BL1-lRg3hZvf2J-Wy7AmxNgkjVjH02wPv3lZCspV0un748cFnMPHqNO1mOwZRYRbdZu8v9p5MM_8Xb0wZeS93jANExzDGUoGnRimurbZT-W9YCmrIZsKP8FgWi0LQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1531954232</pqid></control><display><type>article</type><title>Bruton tyrosine kinase mediates TLR9 -dependent human dendritic cell activation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lougaris, Vassilios, MD ; Baronio, Manuela, PhD ; Vitali, Massimiliano, PhD ; Tampella, Giacomo, PhD ; Cattalini, Marco, MD ; Tassone, Laura, PhD ; Soresina, Annarosa, MD ; Badolato, Raffaele, MD, PhD ; Plebani, Alessandro, MD, PhD</creator><creatorcontrib>Lougaris, Vassilios, MD ; Baronio, Manuela, PhD ; Vitali, Massimiliano, PhD ; Tampella, Giacomo, PhD ; Cattalini, Marco, MD ; Tassone, Laura, PhD ; Soresina, Annarosa, MD ; Badolato, Raffaele, MD, PhD ; Plebani, Alessandro, MD, PhD</creatorcontrib><description>Background Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; however, the TLR9 pathway has never been studied in dendritic cells (DCs) of patients with XLA. Objective The aim of this study was to investigate the role of BTK in human DC activation upon TLR9 stimulation. Methods DCs of patients with XLA and healthy donors were stimulated via TLR4/9 and evaluated for cell activation and cytokine production. Results We showed that BTK plays an essential role in DC responses to unmethylated CpG oligodeoxynucleotide: although responses to lipopolysaccaride/TLR4 induce normal DC activation in terms of upregulation of specific markers (CD86, CD83, CD80, HLA-DR), the CpG/TLR9 pathway is completely impaired in patients with XLA. Furthermore, cytokine production upon TLR9 activation in patients with XLA is radically impaired in terms of IL-6, IL-12, TNF-α, and IL-10 production. Interestingly, BTK mediated STAT1/3 upregulation in a TLR9-dependent manner. The important role of BTK in human DC activation was confirmed after incubation of healthy DCs with ibrutinib, the specific BTK inhibitor, which resulted in impairment of TLR9 responses as seen in patients with XLA. Conclusion Analysis of these data suggests that BTK regulates human DC responses upon TLR9 engagement in terms of activation, cytokine production, and STAT1/3 upregulation. These findings may be of important significance for better understanding and managing different clinical conditions, such as agammaglobulinemia and lymphoid malignancies.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2013.12.1085</identifier><identifier>PMID: 24612681</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Agammaglobulinemia - genetics ; Agammaglobulinemia - immunology ; Agammaglobulinemia - metabolism ; Allergy and Immunology ; Biological and medical sciences ; BTK ; Cytokines - biosynthesis ; dendritic cells ; Dendritic Cells - drug effects ; Dendritic Cells - immunology ; Dendritic Cells - metabolism ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Genetic Diseases, X-Linked - genetics ; Genetic Diseases, X-Linked - immunology ; Genetic Diseases, X-Linked - metabolism ; Humans ; Immunopathology ; Immunophenotyping ; Lipopolysaccharides - immunology ; Lipopolysaccharides - pharmacology ; Medical sciences ; Oligodeoxyribonucleotides - pharmacology ; Phenotype ; Protein-Tyrosine Kinases - metabolism ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; STAT1 ; STAT1 Transcription Factor - metabolism ; STAT3 ; STAT3 Transcription Factor - metabolism ; TLR9 ; Toll-Like Receptor 9 - metabolism</subject><ispartof>Journal of allergy and clinical immunology, 2014-06, Vol.133 (6), p.1644-1650.e4</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2014 American Academy of Allergy, Asthma & Immunology</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-7b0647eae3dc2f3d8775481c73f0602973e1dde5f9aaece168729d9cb31f33db3</citedby><cites>FETCH-LOGICAL-c522t-7b0647eae3dc2f3d8775481c73f0602973e1dde5f9aaece168729d9cb31f33db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2013.12.1085$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28580390$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24612681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lougaris, Vassilios, MD</creatorcontrib><creatorcontrib>Baronio, Manuela, PhD</creatorcontrib><creatorcontrib>Vitali, Massimiliano, PhD</creatorcontrib><creatorcontrib>Tampella, Giacomo, PhD</creatorcontrib><creatorcontrib>Cattalini, Marco, MD</creatorcontrib><creatorcontrib>Tassone, Laura, PhD</creatorcontrib><creatorcontrib>Soresina, Annarosa, MD</creatorcontrib><creatorcontrib>Badolato, Raffaele, MD, PhD</creatorcontrib><creatorcontrib>Plebani, Alessandro, MD, PhD</creatorcontrib><title>Bruton tyrosine kinase mediates TLR9 -dependent human dendritic cell activation</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Background Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; however, the TLR9 pathway has never been studied in dendritic cells (DCs) of patients with XLA. Objective The aim of this study was to investigate the role of BTK in human DC activation upon TLR9 stimulation. Methods DCs of patients with XLA and healthy donors were stimulated via TLR4/9 and evaluated for cell activation and cytokine production. Results We showed that BTK plays an essential role in DC responses to unmethylated CpG oligodeoxynucleotide: although responses to lipopolysaccaride/TLR4 induce normal DC activation in terms of upregulation of specific markers (CD86, CD83, CD80, HLA-DR), the CpG/TLR9 pathway is completely impaired in patients with XLA. Furthermore, cytokine production upon TLR9 activation in patients with XLA is radically impaired in terms of IL-6, IL-12, TNF-α, and IL-10 production. Interestingly, BTK mediated STAT1/3 upregulation in a TLR9-dependent manner. The important role of BTK in human DC activation was confirmed after incubation of healthy DCs with ibrutinib, the specific BTK inhibitor, which resulted in impairment of TLR9 responses as seen in patients with XLA. Conclusion Analysis of these data suggests that BTK regulates human DC responses upon TLR9 engagement in terms of activation, cytokine production, and STAT1/3 upregulation. These findings may be of important significance for better understanding and managing different clinical conditions, such as agammaglobulinemia and lymphoid malignancies.</description><subject>Agammaglobulinemia - genetics</subject><subject>Agammaglobulinemia - immunology</subject><subject>Agammaglobulinemia - metabolism</subject><subject>Allergy and Immunology</subject><subject>Biological and medical sciences</subject><subject>BTK</subject><subject>Cytokines - biosynthesis</subject><subject>dendritic cells</subject><subject>Dendritic Cells - drug effects</subject><subject>Dendritic Cells - immunology</subject><subject>Dendritic Cells - metabolism</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Genetic Diseases, X-Linked - genetics</subject><subject>Genetic Diseases, X-Linked - immunology</subject><subject>Genetic Diseases, X-Linked - metabolism</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Immunophenotyping</subject><subject>Lipopolysaccharides - immunology</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Medical sciences</subject><subject>Oligodeoxyribonucleotides - pharmacology</subject><subject>Phenotype</subject><subject>Protein-Tyrosine Kinases - metabolism</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>STAT1</subject><subject>STAT1 Transcription Factor - metabolism</subject><subject>STAT3</subject><subject>STAT3 Transcription Factor - metabolism</subject><subject>TLR9</subject><subject>Toll-Like Receptor 9 - metabolism</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkltrFDEUgIModm39BYLMi-DLrDnJzCR5UKhFrbBQsPU5ZJMzmOlsZk0yhf33ZthVwRf7lAvfufCdQ8groGug0L0b1oOxfs0o8DWw8ifbJ2QFVIm6k6x9SlaUKqg70agz8iKlgZY3l-o5OWNNB6yTsCI3H-Ocp1DlQ5ySD1jd-2ASVjt03mRM1d3mm6pqh3sMDkOufsw7E6pyddFnbyuL41gZm_2DyX4KF-RZb8aEL0_nOfn--dPd1XW9ufny9epyU9uWsVyLLe0agQa5s6znTgrRNhKs4D3tKFOCIziHba-MQYvQScGUU3bLoefcbfk5eXvMu4_TzxlT1jufll5MwGlOGlpe8jVNSx-DgmobxllB-RG1xUaK2Ot99DsTDxqoXqTrQS_S9SJdA9OL9BL1-lRg3hZvf2J-Wy7AmxNgkjVjH02wPv3lZCspV0un748cFnMPHqNO1mOwZRYRbdZu8v9p5MM_8Xb0wZeS93jANExzDGUoGnRimurbZT-W9YCmrIZsKP8FgWi0LQ</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Lougaris, Vassilios, MD</creator><creator>Baronio, Manuela, PhD</creator><creator>Vitali, Massimiliano, PhD</creator><creator>Tampella, Giacomo, PhD</creator><creator>Cattalini, Marco, MD</creator><creator>Tassone, Laura, PhD</creator><creator>Soresina, Annarosa, MD</creator><creator>Badolato, Raffaele, MD, PhD</creator><creator>Plebani, Alessandro, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20140601</creationdate><title>Bruton tyrosine kinase mediates TLR9 -dependent human dendritic cell activation</title><author>Lougaris, Vassilios, MD ; Baronio, Manuela, PhD ; Vitali, Massimiliano, PhD ; Tampella, Giacomo, PhD ; Cattalini, Marco, MD ; Tassone, Laura, PhD ; Soresina, Annarosa, MD ; Badolato, Raffaele, MD, PhD ; Plebani, Alessandro, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-7b0647eae3dc2f3d8775481c73f0602973e1dde5f9aaece168729d9cb31f33db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Agammaglobulinemia - genetics</topic><topic>Agammaglobulinemia - immunology</topic><topic>Agammaglobulinemia - metabolism</topic><topic>Allergy and Immunology</topic><topic>Biological and medical sciences</topic><topic>BTK</topic><topic>Cytokines - biosynthesis</topic><topic>dendritic cells</topic><topic>Dendritic Cells - drug effects</topic><topic>Dendritic Cells - immunology</topic><topic>Dendritic Cells - metabolism</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Genetic Diseases, X-Linked - genetics</topic><topic>Genetic Diseases, X-Linked - immunology</topic><topic>Genetic Diseases, X-Linked - metabolism</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Immunophenotyping</topic><topic>Lipopolysaccharides - immunology</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Medical sciences</topic><topic>Oligodeoxyribonucleotides - pharmacology</topic><topic>Phenotype</topic><topic>Protein-Tyrosine Kinases - metabolism</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>STAT1</topic><topic>STAT1 Transcription Factor - metabolism</topic><topic>STAT3</topic><topic>STAT3 Transcription Factor - metabolism</topic><topic>TLR9</topic><topic>Toll-Like Receptor 9 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lougaris, Vassilios, MD</creatorcontrib><creatorcontrib>Baronio, Manuela, PhD</creatorcontrib><creatorcontrib>Vitali, Massimiliano, PhD</creatorcontrib><creatorcontrib>Tampella, Giacomo, PhD</creatorcontrib><creatorcontrib>Cattalini, Marco, MD</creatorcontrib><creatorcontrib>Tassone, Laura, PhD</creatorcontrib><creatorcontrib>Soresina, Annarosa, MD</creatorcontrib><creatorcontrib>Badolato, Raffaele, MD, PhD</creatorcontrib><creatorcontrib>Plebani, Alessandro, MD, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lougaris, Vassilios, MD</au><au>Baronio, Manuela, PhD</au><au>Vitali, Massimiliano, PhD</au><au>Tampella, Giacomo, PhD</au><au>Cattalini, Marco, MD</au><au>Tassone, Laura, PhD</au><au>Soresina, Annarosa, MD</au><au>Badolato, Raffaele, MD, PhD</au><au>Plebani, Alessandro, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bruton tyrosine kinase mediates TLR9 -dependent human dendritic cell activation</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>133</volume><issue>6</issue><spage>1644</spage><epage>1650.e4</epage><pages>1644-1650.e4</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>Background Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; however, the TLR9 pathway has never been studied in dendritic cells (DCs) of patients with XLA. Objective The aim of this study was to investigate the role of BTK in human DC activation upon TLR9 stimulation. Methods DCs of patients with XLA and healthy donors were stimulated via TLR4/9 and evaluated for cell activation and cytokine production. Results We showed that BTK plays an essential role in DC responses to unmethylated CpG oligodeoxynucleotide: although responses to lipopolysaccaride/TLR4 induce normal DC activation in terms of upregulation of specific markers (CD86, CD83, CD80, HLA-DR), the CpG/TLR9 pathway is completely impaired in patients with XLA. Furthermore, cytokine production upon TLR9 activation in patients with XLA is radically impaired in terms of IL-6, IL-12, TNF-α, and IL-10 production. Interestingly, BTK mediated STAT1/3 upregulation in a TLR9-dependent manner. The important role of BTK in human DC activation was confirmed after incubation of healthy DCs with ibrutinib, the specific BTK inhibitor, which resulted in impairment of TLR9 responses as seen in patients with XLA. Conclusion Analysis of these data suggests that BTK regulates human DC responses upon TLR9 engagement in terms of activation, cytokine production, and STAT1/3 upregulation. These findings may be of important significance for better understanding and managing different clinical conditions, such as agammaglobulinemia and lymphoid malignancies.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>24612681</pmid><doi>10.1016/j.jaci.2013.12.1085</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-6749 |
ispartof | Journal of allergy and clinical immunology, 2014-06, Vol.133 (6), p.1644-1650.e4 |
issn | 0091-6749 1097-6825 |
language | eng |
recordid | cdi_proquest_miscellaneous_1534814450 |
source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Agammaglobulinemia - genetics Agammaglobulinemia - immunology Agammaglobulinemia - metabolism Allergy and Immunology Biological and medical sciences BTK Cytokines - biosynthesis dendritic cells Dendritic Cells - drug effects Dendritic Cells - immunology Dendritic Cells - metabolism Fundamental and applied biological sciences. Psychology Fundamental immunology Genetic Diseases, X-Linked - genetics Genetic Diseases, X-Linked - immunology Genetic Diseases, X-Linked - metabolism Humans Immunopathology Immunophenotyping Lipopolysaccharides - immunology Lipopolysaccharides - pharmacology Medical sciences Oligodeoxyribonucleotides - pharmacology Phenotype Protein-Tyrosine Kinases - metabolism Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis STAT1 STAT1 Transcription Factor - metabolism STAT3 STAT3 Transcription Factor - metabolism TLR9 Toll-Like Receptor 9 - metabolism |
title | Bruton tyrosine kinase mediates TLR9 -dependent human dendritic cell activation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T03%3A18%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bruton%20tyrosine%20kinase%20mediates%20TLR9%20-dependent%20human%20dendritic%20cell%20activation&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Lougaris,%20Vassilios,%20MD&rft.date=2014-06-01&rft.volume=133&rft.issue=6&rft.spage=1644&rft.epage=1650.e4&rft.pages=1644-1650.e4&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/j.jaci.2013.12.1085&rft_dat=%3Cproquest_cross%3E1531954232%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1531954232&rft_id=info:pmid/24612681&rft_els_id=1_s2_0_S0091674914000840&rfr_iscdi=true |